Join NPC and key stakeholders on Jan. 30 at 1 p.m. ET for a webinar that will explore the Food and Drug Administration's recently released real-world evidence framework and examine the framework's implications for patients, payers, manufacturers and other health care stakeholders.

In NPC's comments on the International Pricing Index Model for Medicare Part B Drugs, we identify critical methodological limitations associated with the IPI Model, which ultimately undermine the agency’s goal of prioritizing value and improved patient outcomes, over utilization and sickness.

In his latest column for Chain Drug Review, National Pharmaceutical Council President and Chief Executive Officer Dan Leonard looks deeper into 2019 and explores how we can take a more holistic approach toward addressing health care spending and getting it under control.